Review Article
First-line treatment strategies and potential prognostic factors in patients with KRAS G12C-mutant non-small cell lung cancer
AME Clinical Trials Review
2026;
4:
1
.
(25 February 2026)
Editorial Commentary
Linvoseltamab, a new BCMA-targeting bispecific antibody for multiple myeloma: linking new with existing data
AME Clinical Trials Review
2025;
3:
65
.
(25 December 2025)
Editorial Commentary
Challenging the status quo: ivonescimab’s bid to displace anti-PD-(L)1 inhibitors
AME Clinical Trials Review
2025;
3:
64
.
(25 December 2025)
Editorial Commentary
PEARL trial: efficacy and challenges of durvalumab monotherapy in metastatic non-small cell lung cancer with PD-L1 expression of ≥25%
AME Clinical Trials Review
2025;
3:
63
.
(25 December 2025)
Editorial Commentary
Recent developments in HER2-targeted therapy for patients with HER2-positive metastatic breast cancer: insights from the latest DESTINY-Breast12 trial results
AME Clinical Trials Review
2025;
3:
62
.
(25 December 2025)
Editorial Commentary
Beyond the surface: the hidden aggression of visceral pleural invasion in early-stage non-small cell lung cancer
AME Clinical Trials Review
2025;
3:
61
.
(25 December 2025)
Editorial Commentary
Insights into long-term safety and efficacy of evinacumab in homozygous familial hypercholesterolaemia
AME Clinical Trials Review
2025;
3:
60
.
(25 December 2025)
Editorial Commentary
Third- and later-line systemic therapy in metastatic gastric cancer: a persistent unmet need
AME Clinical Trials Review
2025;
3:
59
.
(25 December 2025)
Editorial Commentary
Six-year results of the CLL14 study—redefining long-term outcomes in chronic lymphocytic leukemia management
AME Clinical Trials Review
2025;
3:
58
.
(25 December 2025)
Editorial Commentary
Breaking through complexity: the expanding role of optical coherence tomography in PCI of complex coronary lesions
AME Clinical Trials Review
2025;
3:
57
.
(25 December 2025)
Editorial Commentary
Optimizing the adjuvant chemotherapy for HER2-positive early breast cancer
AME Clinical Trials Review
2025;
3:
56
.
(25 December 2025)
Editorial Commentary
Should we not use neurokinin-1 receptor antagonists in the prevention of trastuzumab deruxtecan-induced nausea and vomiting?—Putting the results of the ERICA study into perspective
AME Clinical Trials Review
2025;
3:
55
.
(25 December 2025)
Editorial Commentary
Epcoritamab: the next frontier in the treatment of relapsed/refractory follicular lymphoma
AME Clinical Trials Review
2025;
3:
54
.
(25 December 2025)
Letter to the Editor
Immunotherapy in early HR+ breast cancer: lessons from KN-756 and CM-7FL
AME Clinical Trials Review
2025;
3:
53
.
(25 October 2025)
Editorial Commentary
Inferiority of coronary paclitaxel-coated balloon angioplasty to sirolimus-eluting stents for de novo non-complex lesions without a restriction of target vessel diameter: the REC-CAGEFREE I trial
AME Clinical Trials Review
2025;
3:
52
.
(25 October 2025)
Editorial Commentary
Post-CDK4/6i wars in HR+/HER2− breast cancer: is elacestrant a solid contender through the lens of precision oncology
AME Clinical Trials Review
2025;
3:
51
.
(25 October 2025)
Editorial Commentary
Quality of life during treatment with trastuzumab deruxtecan—is quality of life maintained due to high efficacy?
AME Clinical Trials Review
2025;
3:
50
.
(25 October 2025)
Editorial Commentary
Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: light and gloom
AME Clinical Trials Review
2025;
3:
49
.
(25 October 2025)
Editorial Commentary
Cabozantinib: a promising advancement in the treatment of advanced neuroendocrine tumors
AME Clinical Trials Review
2025;
3:
48
.
(25 October 2025)
Editorial Commentary
Early implementation of exercise after breast cancer surgery: insights and opportunity
AME Clinical Trials Review
2025;
3:
47
.
(25 October 2025)
Editorial Commentary
Sex-specific approach to only optimize acetylsalicylic acid dosing for secondary prevention in cardiovascular disease is definitely questionable—insights from the ADAPTABLE trial and beyond
AME Clinical Trials Review
2025;
3:
46
.
(25 October 2025)
Editorial Commentary
The central nervous system protective activity of selpercatinib from LIBRETTO-431
AME Clinical Trials Review
2025;
3:
45
.
(25 October 2025)
Review Article
Recent updates in targeted therapy for advanced non-small cell lung cancer with actionable genomic alterations: a narrative review
AME Clinical Trials Review
2025;
3:
44
.
(25 October 2025)
Editorial Commentary
Quadruplet therapy for extensive-stage small cell lung cancer (ES-SCLC): does one size fit all in treatment for ES-SCLC?
AME Clinical Trials Review
2025;
3:
43
.
(25 August 2025)
Editorial Commentary
Aspirin therapy for secondary prevention of atherosclerotic cardiovascular disease: should we be tailoring according to sex?
AME Clinical Trials Review
2025;
3:
42
.
(25 August 2025)
Editorial Commentary
Dual attack on multiple myeloma: targeting BCMA and CD19
AME Clinical Trials Review
2025;
3:
41
.
(25 August 2025)
Editorial Commentary
The CLL2-BAAG trial provides further evidence supporting a minimal residual disease driven approach and triple therapy in relapsed chronic lymphocytic leukaemia
AME Clinical Trials Review
2025;
3:
40
.
(25 August 2025)
Editorial Commentary
Is there a role for triple chemotherapy in advanced biliary tract cancer?
AME Clinical Trials Review
2025;
3:
39
.
(25 August 2025)
Editorial Commentary
Abiraterone + olaparib in metastatic castration-resistant prostate cancer: tolerable, not toxic
AME Clinical Trials Review
2025;
3:
38
.
(25 August 2025)
Editorial Commentary
The UNION trial: open the door to immune checkpoint inhibitors for proficient mismatch repair/microsatellite stability rectal cancer?
AME Clinical Trials Review
2025;
3:
37
.
(25 August 2025)